<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40581185</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-1929</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Revista espanola de anestesiologia y reanimacion</Title><ISOAbbreviation>Rev Esp Anestesiol Reanim (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Predictors of response in patients with traumatic peripheral neuropathic pain treated with the 8% capsaicin patch.</ArticleTitle><Pagination><StartPage>501880</StartPage><MedlinePgn>501880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redare.2025.501880</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2341-1929(25)00201-X</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Neuropathic pain (NP) is a widespread, complex disorder that responds differently to pharmacological treatment. The aim of this study was to identify the baseline characteristics of good response to capsaicin 8% patch in patients with trauma-induced peripheral neuropathic pain (PNP).</AbstractText><AbstractText Label="MATERIALS AND METHODS">We performed a prospective, longitudinal, open-label study in 31 patients with PNP treated with 1-3 applications of the capsaicin 8% patch for 52 weeks. Response to treatment was defined as a reduction in the Visual Analogue Scale (VAS) score compared to baseline. Data from responders and non-responders were compared at the start (month 1) and end (month 12) of treatment. Logistic regression was used to identify predictors of treatment response.</AbstractText><AbstractText Label="RESULTS">At month 1, responders (n = 17) had significantly larger treatment areas (155.18 cm<sup>2</sup> vs. 59.21 cm<sup>2</sup>; p = 0.004) and reported greater pain relief with treatments received in the previous week in the brief pain questionnaire (34.7% vs. 14.3%; p = 0.023). At month 12, significant predictors included cold allodynia (OR 8; p = 0.030), positive for painful cold in the DN4 questionnaire (OR 7.936; p = 0.019), no penetrating pain (OR 16.800; p = 0.009), and pain interference with work score &lt;7.5 (OR 7.917; p = 0.019).</AbstractText><AbstractText Label="CONCLUSIONS">This study makes a significant contribution to the management of post-traumatic peripheral neuropathic pain by providing tools to personalise treatment and optimize available resources.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monteagudo Moreno</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a y Reanimaci&#xf3;n, Hospital MAZ, Zaragoza, Spain. Electronic address: lauramonteagudomoreno@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#xed;a Blasco</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio Unidad Dolor Cr&#xf3;nico, Hospital Cl&#xed;nico Universitario Lozano Blesa, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malo Urri&#xe9;s</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PhysiUZerapy Research Group, Facultad de Ciencias de la Salud, Universidad de Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuez Polo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital MAZ, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mar&#xed;n Zald&#xed;var</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a y Reanimaci&#xf3;n, Hospital MAZ, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Anestesiol Reanim (Engl Ed)</MedlineTA><NlmUniqueID>101778594</NlmUniqueID><ISSNLinking>2341-1929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S07O44R1ZM</RegistryNumber><NameOfSubstance UI="D002211">Capsaicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="Y">Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002211" MajorTopicYN="Y">Capsaicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057968" MajorTopicYN="N">Transdermal Patch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Capsaicin patch 8%</Keyword><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico perif&#xe9;rico</Keyword><Keyword MajorTopicYN="N">Parche capsaicina 8%</Keyword><Keyword MajorTopicYN="N">Peripheral neuropathic pain</Keyword><Keyword MajorTopicYN="N">Post-surgical</Keyword><Keyword MajorTopicYN="N">Post-traumatic</Keyword><Keyword MajorTopicYN="N">Postquir&#xfa;rgico</Keyword><Keyword MajorTopicYN="N">Postraum&#xe1;tico</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>28</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40581185</ArticleId><ArticleId IdType="doi">10.1016/j.redare.2025.501880</ArticleId><ArticleId IdType="pii">S2341-1929(25)00201-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31486801</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>4</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Consenso multidisciplinario de diagn&#xf3;stico y tratamiento del dolor neurop&#xe1;tico perif&#xe9;rico y localizado en M&#xe9;xico.</ArticleTitle><Pagination><StartPage>428</StartPage><EndPage>435</EndPage><MedlinePgn>428-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.19005195</ELocationID><Abstract><AbstractText>Neuropathic pain is an entity that causes patient disability and its diagnosis and treatment is a challenge for physicians. In a significant percentage of patients with neuropathic pain, it is restricted to one dermatome or to a particular region of the body; in this case, it is referred to as localized neuropathic pain. There are no Mexican clinical guidelines proposing recommendations for the diagnosis and treatment of localized neuropathic pain in our population. This article presents the recommendations of a multidisciplinary consensus of specialists from different areas involved in the diagnosis and treatment of this type of patients.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lara-Solares</LastName><ForeName>Argelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Departamento de Medicina del Dolor y Paliativa, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayoral-Rojals</LastName><ForeName>V&#xed;ctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Instituto Catal&#xe1;n de la Salud, Hospital Universitario de Bellvitge, Servicio de Anestesiolog&#xed;a, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guill&#xe9;n-N&#xfa;&#xf1;ez</LastName><ForeName>Mar&#xed;a Del Roc&#xed;o</ForeName><Initials>MDR</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cancerolog&#xed;a, Cl&#xed;nica del Dolor, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villafa&#xf1;a-Tello</LastName><ForeName>Jos&#xe9; de Jes&#xfa;s Salvador</ForeName><Initials>JJS</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Oncolog&#xed;a, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cant&#xfa;-Brito</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Unidad de Neurolog&#xed;a, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genis-Rondero</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a, Unidad M&#xe9;dica de Alta Especialidad, Hospital de Ortopedia Magdalena de las Salinas, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nader-Kawachi</LastName><ForeName>Juan Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Cl&#xed;nica M&#xe9;dica Sur, Servicio de Neurolog&#xed;a, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tito-Hern&#xe1;ndez</LastName><ForeName>Hamlet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Consultorio Orthocaz, Unidad de Ortopedia, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salado-&#xc1;vila</LastName><ForeName>Mar&#xed;a Magdalena</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Secretar&#xed;a de Salud, Hospital General "Dr. Manuel Gea Gonz&#xe1;lez", Cl&#xed;nica del Dolor y Calidad de Vida, Divisi&#xf3;n de Cuidados Paliativos, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz-Lozano</LastName><ForeName>Jes&#xfa;s Alfonso De la</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hospital Pedi&#xe1;trico Peralvillo, Ortopedia y Traumatolog&#xed;a, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Ortiz</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Departamento de Medicina del Dolor y Paliativa, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Cantisani</LastName><ForeName>Jos&#xe9; Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Hidalgo, Cl&#xed;nica del dolor, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyva-Rend&#xf3;n</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a "Manuel Velasco Su&#xe1;rez", Unidad de Neurolog&#xed;a, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Santos</LastName><ForeName>Jorge Rafael</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Centro M&#xe9;dico Nacional 20 de Noviembre, Cl&#xed;nica del Dolor, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El dolor neurop&#xe1;tico es una entidad que provoca discapacidad al paciente y su diagn&#xf3;stico y tratamiento es un reto para los m&#xe9;dicos. En un porcentaje importante de pacientes afectados, el dolor neurop&#xe1;tico se presenta circunscrito a un dermatoma o a una regi&#xf3;n concreta del cuerpo, denomin&#xe1;ndose en ese caso dolor neurop&#xe1;tico localizado. No existen gu&#xed;as cl&#xed;nicas mexicanas que postulen recomendaciones para el diagn&#xf3;stico y tratamiento del dolor neurop&#xe1;tico localizado en nuestra poblaci&#xf3;n. En este art&#xed;culo se exponen las recomendaciones de un consenso multidisciplinario realizado con especialistas de distintas &#xe1;reas implicadas en el diagn&#xf3;stico y tratamiento de este tipo de pacientes.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico</Keyword><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico localizado</Keyword><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico perif&#xe9;rico</Keyword><Keyword MajorTopicYN="N">Localized neuropathic pain</Keyword><Keyword MajorTopicYN="N">Neuropathic pain</Keyword><Keyword MajorTopicYN="N">Peripheral neuropathic pain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31486801</ArticleId><ArticleId IdType="doi">10.24875/GMM.19005195</ArticleId><ArticleId IdType="pii">j155/4/428</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31337589</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[Update in the pharmacological treatment of neuropathic pain].</ArticleTitle><Pagination><StartPage>535</StartPage><EndPage>545</EndPage><MedlinePgn>535-545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2019.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(19)30206-0</ELocationID><Abstract><AbstractText>We provide an updated review of the pharmacological treatment of neuropathic pain, with emphasis on the latest evidence-based recommendations. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-noradrenaline reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second-line treatments include 5% lidocaine medicated plasters and capsaicin 8% patches, only for peripheral neuropathic pain and tramadol; whereas potent opioids and botulinum toxin A (for peripheral neuropathic pain) are considered third-line treatments. Future perspectives include the development of new drugs and a more personalised therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Sociedad Espa&#xf1;ola de M&#xe9;dicos de Atenci&#xf3;n Primaria (SEMERGEN). Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alc&#xe1;ntara Montero</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Salud Manuel Encinas, Consultorio de Malpartida de C&#xe1;ceres, C&#xe1;ceres, Espa&#xf1;a; Grupo de Trabajo de Dolor de SEMERGEN. Electronic address: a.alcantara.montero@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibor Vidal</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Centro de Salud Guillem de Castro, Valencia, Espa&#xf1;a; Grupo de Trabajo de Dolor de SEMERGEN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso Verdugo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Salud Guadalajara Perif&#xe9;rico, Guadalajara, Espa&#xf1;a; Grupo de Trabajo de Dolor de SEMERGEN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trillo Calvo</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Salud de Calamocha, Teruel, Espa&#xf1;a; Grupo de Trabajo de Dolor de SEMERGEN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Actualizaci&#xf3;n en el tratamiento farmacol&#xf3;gico del dolor neurop&#xe1;tico.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico</Keyword><Keyword MajorTopicYN="N">Emerging therapies</Keyword><Keyword MajorTopicYN="N">Farmacoterapia</Keyword><Keyword MajorTopicYN="N">Medicina personalizada</Keyword><Keyword MajorTopicYN="N">Neuropathic pain</Keyword><Keyword MajorTopicYN="N">Personalised medicine</Keyword><Keyword MajorTopicYN="N">Pharmacotherapy</Keyword><Keyword MajorTopicYN="N">Recomendaciones</Keyword><Keyword MajorTopicYN="N">Recommendations</Keyword><Keyword MajorTopicYN="N">Terapias emergentes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31337589</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2019.05.008</ArticleId><ArticleId IdType="pii">S1138-3593(19)30206-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31186096</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-3278</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Rehabilitacion</Title><ISOAbbreviation>Rehabilitacion (Madr)</ISOAbbreviation></Journal><ArticleTitle>[Subcutaneous botulinum toxin in the treatment of peripheral neuropathic pain].</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>135</EndPage><MedlinePgn>131-135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rh.2018.12.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0048-7120(19)30001-5</ELocationID><Abstract><AbstractText>Neuropathic pain impairs quality of life in affected individuals and poses a challenge to clinicians due to the complexity of its treatment and frequent therapeutic failures. We present 4clinical cases of chronic neuropathic pain (LANSS &#x2265; 19), refractory to conservative treatment (meralgia paraesthetica, post-surgical pain and 2surgical scars). Subcutaneous botulinum toxin type A was infiltrated periodically over the painful area. All patients experienced subjective improvement in pain and improvement measured by the visual analogic scale. Pain relief started at 5-21 days and continued up to 1.5-3 months, and up to 9 months in one patient. Pain that reappeared was of lower intensity in 3patients and was reduced in area in 2patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Sociedad Espa&#xf1;ola de Rehabilitaci&#xf3;n y Medicina F&#xed;sica. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puentes Guti&#xe9;rrez</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Servicio de Rehabilitaci&#xf3;n, Hospital Virgen de la Salud, Toledo, Espa&#xf1;a. Electronic address: anapuentes@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Bascones</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Rehabilitaci&#xf3;n, Hospital Virgen de la Salud, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puentes Guti&#xe9;rrez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Rehabilitaci&#xf3;n, Hospital Virgen de la Salud, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az Jim&#xe9;nez</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Rehabilitaci&#xf3;n, Hospital Virgen de la Salud, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Toxina botul&#xed;nica subcut&#xe1;nea en el tratamiento del dolor neurop&#xe1;tico perif&#xe9;rico.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rehabilitacion (Madr)</MedlineTA><NlmUniqueID>7802471</NlmUniqueID><ISSNLinking>0048-7120</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019274" MajorTopicYN="N">Botulinum Toxins, Type A</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059350" MajorTopicYN="N">Chronic Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009465" MajorTopicYN="N">Neuromuscular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allodynia</Keyword><Keyword MajorTopicYN="N">Alodinia</Keyword><Keyword MajorTopicYN="N">Botulinum toxin type A</Keyword><Keyword MajorTopicYN="N">Cicatriz</Keyword><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico</Keyword><Keyword MajorTopicYN="N">Hiperalgesia</Keyword><Keyword MajorTopicYN="N">Hyperalgesia</Keyword><Keyword MajorTopicYN="N">Infiltraci&#xf3;n subcut&#xe1;nea</Keyword><Keyword MajorTopicYN="N">Meralgia paraesthetica</Keyword><Keyword MajorTopicYN="N">Meralgia parest&#xe9;sica</Keyword><Keyword MajorTopicYN="N">Neuropathic pain</Keyword><Keyword MajorTopicYN="N">Scar</Keyword><Keyword MajorTopicYN="N">Subcutaneous injection</Keyword><Keyword MajorTopicYN="N">Toxina botul&#xed;nica tipo A</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31186096</ArticleId><ArticleId IdType="doi">10.1016/j.rh.2018.12.002</ArticleId><ArticleId IdType="pii">S0048-7120(19)30001-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27321171</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5808</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurologia</Title><ISOAbbreviation>Neurologia (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.</ArticleTitle><Pagination><StartPage>141</StartPage><EndPage>153</EndPage><MedlinePgn>141-153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nrl.2016.03.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-4853(16)30043-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to analyse the effects of age and sex on pain and cost for patients with chronic peripheral neuropathic pain (PNP) who have started treatment with brand name gabapentin versus generic gabapentin (EFG).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective multicentre study using electronic medical records (EMR) for patients of both sexes, older than 18, who began treatment with brand name or generic gabapentin. Adherence (medication possession ratio [MPR]), persistence, use of healthcare resources, cost, and pain reduction were measured for one year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analysed 1369 EMRs [61.1% women; mean age 64.6 (15.9), 52.4%&#x2265;65 years]; 400 used brand name drugs while 969 used generic gabapentin. Persistence and adherence were higher in patients using brand name gabapentin (7.3 vs 6.3 months, P&lt;.001; 86.5% vs 81.3% MPR, P&lt;.001). Lower healthcare costs were observed in patients using brand-name gabapentin in both age groups (&lt;65 and &#x2265;65). Mean difference in cost per patient amounted to &#x20ac;221 (95%CI: 59-382) and &#x20ac;217 (95%CI: 51-382) in the &lt;65 and &#x2265;65 age groups, respectively (P&lt;.01). Mean difference in cost among men amounted to &#x20ac;197 (63-328), while mean difference in cost among women amounted to &#x20ac;239 (96-397) (P=.005 and P=.004, respectively). Compared with EFG, brand treatment showed greater pain relief: 13.5% (10.9-16.2) and 10.8% (8.2-13.5) in &lt;65 and &#x2265;65year patients, respectively (P&lt;.001), and 10.7% (8.2-13.2) and 13.8% (11.0-16.5) in women and men respectively (P&lt;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Regardless of sex and age, patients who started PNP treatment with brand name medication showed greater persistence and adherence to treatment than those taking generic drugs. Brand name treatment also involved lower healthcare costs, and greater pain relief.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Sociedad Espa&#xf1;ola de Neurolog&#xed;a. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Navarro-Artieda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Documentaci&#xf3;n M&#xe9;dica, Hospital Germans Trias i Pujol, Badalona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rejas-Guti&#xe9;rrez</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Farmacoeconom&#xed;a e Investigaci&#xf3;n de Resultados en Salud, Pfizer SLU, Alcobendas, Madrid, Espa&#xf1;a. Electronic address: Javier.rejas@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Paramo</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento M&#xe9;dico, Pfizer GEP SLU, Alcobendas, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sicras-Mainar</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CAP Vicen&#xe7; Papaciet, La Roca del Vall&#xe8;s, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><VernacularTitle>Efecto de la edad y el g&#xe9;nero sobre las consecuencias cl&#xed;nicas y econ&#xf3;micas del tratamiento con especialidad farmac&#xe9;utica de marca o gen&#xe9;rica en pacientes con dolor neurop&#xe1;tico perif&#xe9;rico en pr&#xe1;ctica cl&#xed;nica habitual.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurologia (Engl Ed)</MedlineTA><NlmUniqueID>101778590</NlmUniqueID><ISSNLinking>2173-5808</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="N">Cyclohexanecarboxylic Acids</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Adherencia</Keyword><Keyword MajorTopicYN="N">Brand name drugs</Keyword><Keyword MajorTopicYN="N">Costes</Keyword><Keyword MajorTopicYN="N">Costs</Keyword><Keyword MajorTopicYN="N">Dolor neurop&#xe1;tico</Keyword><Keyword MajorTopicYN="N">Gabapentin</Keyword><Keyword MajorTopicYN="N">Gabapentina</Keyword><Keyword MajorTopicYN="N">Generic drugs</Keyword><Keyword MajorTopicYN="N">Gen&#xe9;ricos</Keyword><Keyword MajorTopicYN="N">Medicamentos de marca</Keyword><Keyword MajorTopicYN="N">Neuropathic pain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27321171</ArticleId><ArticleId IdType="doi">10.1016/j.nrl.2016.03.012</ArticleId><ArticleId IdType="pii">S0213-4853(16)30043-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>